Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Recommendation of “Buy” by Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been assigned an average recommendation of “Buy” from the nine brokerages that are presently covering the firm, MarketBeat.com reports. Nine analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have covered the stock in the last year is $74.86.

JSPR has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research report on Thursday, October 24th. Royal Bank of Canada lowered their target price on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a report on Wednesday, August 14th. JMP Securities reiterated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Evercore ISI reissued an “outperform” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research report on Monday, August 26th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th.

Institutional Trading of Jasper Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its stake in Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after buying an additional 1,698 shares in the last quarter. Wolff Wiese Magana LLC acquired a new position in shares of Jasper Therapeutics in the 3rd quarter valued at $59,000. MetLife Investment Management LLC lifted its holdings in shares of Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after acquiring an additional 3,873 shares during the period. Jane Street Group LLC bought a new stake in Jasper Therapeutics in the third quarter valued at about $251,000. Finally, Rhumbline Advisers acquired a new position in Jasper Therapeutics in the second quarter worth about $300,000. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Trading Down 7.6 %

NASDAQ:JSPR opened at $20.43 on Tuesday. The firm has a market capitalization of $308.60 million, a PE ratio of -4.31 and a beta of 2.19. Jasper Therapeutics has a 1 year low of $4.00 and a 1 year high of $31.01. The firm’s fifty day simple moving average is $20.25 and its 200 day simple moving average is $20.94.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.